Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


15.10.2018

1 AJR Am J Roentgenol
2 BJU Int
1 BMC Cancer
2 BMC Urol
1 Cancer Lett
1 Clin Cancer Res
2 Eur J Radiol
8 Eur Urol
1 Hum Pathol
1 Int J Cancer
1 Int J Radiat Oncol Biol Phys
1 J Clin Oncol
1 J Magn Reson Imaging
2 J Natl Cancer Inst
1 J Nucl Med
1 J Urol
1 Lancet Oncol
3 N Engl J Med
1 Oncogene
1 Oncol Rep
1 Prostate
1 Urology


   Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. JENA A, Taneja R, Taneja S, Singh A, et al
    Improving Diagnosis of Primary Prostate Cancer With Combined (68)Ga-Prostate-Specific Membrane Antigen-HBED-CC Simultaneous PET and Multiparametric MRI and Clinical Parameters.
    AJR Am J Roentgenol. 2018 Oct 9:1-8. doi: 10.2214/AJR.18.19585.
    PubMed     Text format     Abstract available


    BJU Int

  2. PINSKY PF, Miller E, Prorok P, Grubb R, et al
    Extended follow-up for prostate cancer incidence and mortality in the PLCO randomized cancer screening trial.
    BJU Int. 2018 Oct 5. doi: 10.1111/bju.14580.
    PubMed     Text format     Abstract available

  3. GIELCHINSKY I, Chang J, Cusick T, Delprado W, et al
    Prostate Cancer in 432 men under the age of 50 years in the Prostate Specific Antigen era - a new outlook.
    BJU Int. 2018 Oct 10. doi: 10.1111/bju.14586.
    PubMed     Text format     Abstract available


    BMC Cancer

  4. JIVIDEN K, Kedzierska KZ, Yang CS, Szlachta K, et al
    Genomic analysis of DNA repair genes and androgen signaling in prostate cancer.
    BMC Cancer. 2018;18:960.
    PubMed     Text format     Abstract available


    BMC Urol

  5. SCHULTZ NM, Shore ND, Chowdhury S, Klotz LH, et al
    Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.
    BMC Urol. 2018;18:84.
    PubMed     Text format     Abstract available

  6. WASHINO S, Kobayashi S, Okochi T, Kameda T, et al
    Cancer detection rate of prebiopsy MRI with subsequent systematic and targeted biopsy are superior to non-targeting systematic biopsy without MRI in biopsy naive patients: a retrospective cohort study.
    BMC Urol. 2018;18:51.
    PubMed     Text format     Abstract available


    Cancer Lett

  7. CHEN WY, Zeng T, Wen YC, Yeh HL, et al
    Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
    Cancer Lett. 2018 Oct 9. pii: S0304-3835(18)30610.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  8. TAGAWA ST, Antonarakis ES, Gjyrezi A, Galletti G, et al
    Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY.
    Clin Cancer Res. 2018 Oct 9. pii: 1078-0432.CCR-18-0320.
    PubMed     Text format     Abstract available


    Eur J Radiol

  9. SAUER M, Klene C, Kaul M, Quitzke A, et al
    Preoperative evaluation of pelvine lymph node metastasis in high risk prostate cancer with intravoxel incoherent motion (IVIM) MRI.
    Eur J Radiol. 2018;107:1-6.
    PubMed     Text format     Abstract available

  10. MA S, Xu K, Xie H, Wang H, et al
    Diagnostic efficacy of b value (2000 s/mm(2)) diffusion-weighted imaging for prostate cancer: Comparison of a reduced field of view sequence and a conventional technique.
    Eur J Radiol. 2018;107:125-133.
    PubMed     Text format     Abstract available


    Eur Urol

  11. TOSCO L, Briganti A, D'amico AV, Eastham J, et al
    Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer.
    Eur Urol. 2018 Oct 1. pii: S0302-2838(18)30549.
    PubMed     Text format     Abstract available

  12. LI W, Middha M, Bicak M, Sjoberg DD, et al
    Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.
    Eur Urol. 2018 Jul 7. pii: S0302-2838(18)30446.
    PubMed     Text format     Abstract available

  13. CULIG Z
    Identification of Potential Novel Candidates for Understanding Racial Differences in Prostate Cancer.
    Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30726.
    PubMed     Text format    

  14. CARTER HB, Helfand B, Mamawala M, Wu Y, et al
    Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
    Eur Urol. 2018 Oct 8. pii: S0302-2838(18)30684.
    PubMed     Text format     Abstract available

  15. PERNAR CH, Ebot EM, Pettersson A, Graff RE, et al
    A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
    Eur Urol. 2018 Oct 6. pii: S0302-2838(18)30730.
    PubMed     Text format     Abstract available

  16. FOSSATI N, Suardi N, Gandaglia G, Bravi CA, et al
    Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.
    Eur Urol. 2018 Oct 6. pii: S0302-2838(18)30659.
    PubMed     Text format     Abstract available

  17. MOSCHINI M, Zaffuto E, Karakiewicz PI, Andrea DD, et al
    External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
    Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30722.
    PubMed     Text format     Abstract available

  18. ISAACSSON VELHO P, Qazi F, Hassan S, Carducci MA, et al
    Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
    Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30729.
    PubMed     Text format     Abstract available


    Hum Pathol

  19. NAKAMURA Y, Ise K, McNamara KM, Azmahani A, et al
    The expression of sex steroid receptors and sex steroid-synthesizing/metabolizing enzymes in metastasized lymph nodes of prostate Cancer.
    Hum Pathol. 2018 Oct 2. pii: S0046-8177(18)30374.
    PubMed     Text format     Abstract available


    Int J Cancer

  20. ZHANG AY, Chiam K, Haupt Y, Fox S, et al
    An Analysis of a Multiple Biomarker Panel to Better Predict Prostate Cancer Metastasis After Radical Prostatectomy.
    Int J Cancer. 2018 Oct 4. doi: 10.1002/ijc.31906.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  21. CROOK JM, Zhang P, Pisansky TM, Trabulsi EJ, et al
    A Prospective Phase II Trial of Trans-perineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer after External Beam Radiotherapy (NRG Oncology/RTOG -0526).
    Int J Radiat Oncol Biol Phys. 2018 Oct 9. pii: S0360-3016(18)33830.
    PubMed     Text format     Abstract available


    J Clin Oncol

  22. MORGAN SC, Hoffman K, Loblaw DA, Buyyounouski MK, et al
    Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.
    J Clin Oncol. 2018 Oct 11:JCO1801097. doi: 10.1200/JCO.18.01097.
    PubMed     Text format    


    J Magn Reson Imaging

  23. WANG S, Fan X, Yousuf A, Eggener SE, et al
    Evaluation of Focal Laser Ablation of Prostate Cancer Using High Spectral and Spatial Resolution Imaging: A Pilot Study.
    J Magn Reson Imaging. 2018 Oct 6. doi: 10.1002/jmri.26538.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  24. YOO YA, Vatapalli R, Lysy B, Mok H, et al
    The Role of Castration-Resistant Bmi1+Sox2+ Cells in Driving Recurrence in Prostate Cancer.
    J Natl Cancer Inst. 2018 Oct 11. pii: 5127127. doi: 10.1093.
    PubMed     Text format     Abstract available

  25. KARTHAUS WR, Sawyers CL
    Strategies to Identify and Target Cells of Origin in Prostate Cancer.
    J Natl Cancer Inst. 2018 Oct 11. pii: 5127123. doi: 10.1093.
    PubMed     Text format    


    J Nucl Med

  26. VIOLET JA, Jackson P, Ferdinandus J, Sandhu S, et al
    Dosimetry of Lu-177 PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pre-therapeutic imaging and "whole body" tumor dosimetry with treatment outcomes.
    J Nucl Med. 2018 Oct 5. pii: jnumed.118.219352. doi: 10.2967/jnumed.118.219352.
    PubMed     Text format     Abstract available


    J Urol

  27. ITO Y, Udo K, Vertosick EA, Sjoberg DD, et al
    Clinical Utility of Prostate and Tumor Volume-Related Parameters Following Radical Prostatectomy for Localized Prostate Cancer.
    J Urol. 2018 Oct 6. pii: S0022-5347(18)43967-5. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


    Lancet Oncol

  28. LECOUVET FE, Oprea-Lager DE, Liu Y, Ost P, et al
    Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group.
    Lancet Oncol. 2018;19:e534-e545.
    PubMed     Text format     Abstract available


    N Engl J Med

  29. BREGNI G, Rebuzzi SE, Fornarini G
    Enzalutamide in Castration-Resistant Prostate Cancer.
    N Engl J Med. 2018;379:1380-1.
    PubMed     Text format    

  30. ANKER MS, Lehmann LH, Ander SD
    Enzalutamide in Castration-Resistant Prostate Cancer.
    N Engl J Med. 2018;379:1380.
    PubMed     Text format    

  31. VEDULA R, Vaidya A, Galetta K, Laubach J, et al
    A Sticky Situation.
    N Engl J Med. 2018;379:e22.
    PubMed     Text format    


    Oncogene

  32. METT V, Komarova EA, Greene K, Bespalov I, et al
    Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy.
    Oncogene. 2018;37:439-449.
    PubMed     Text format     Abstract available


    Oncol Rep

  33. DIAO X, Chen X, Pi Y, Zhang Y, et al
    Androgen receptor induces EPHA3 expression by interacting with transcription factor SP1.
    Oncol Rep. 2018;40:1174-1184.
    PubMed     Text format     Abstract available


    Prostate

  34. ERYILMAZ IE, Aytac Vuruskan B, Kaygisiz O, Egeli U, et al
    RNA-based markers in biopsy cores with atypical small acinar proliferation: Predictive effect of T2E fusion positivity and MMP-2 upregulation for a subsequent prostate cancer diagnosis.
    Prostate. 2018 Oct 7. doi: 10.1002/pros.23724.
    PubMed     Text format     Abstract available


    Urology

  35. ALBALA D, Manak MS, Varsanik JS, Rashid HH, et al
    Clinical proof-of-concept of a novel platform utilizing biopsy-derived live single cells, phenotypic biomarkers, and machine learning toward a precision risk stratification test for Prostate Cancer Grade Groups 1 and 2 (Gleason 3+3 and 3+4).
    Urology. 2018 Oct 9. pii: S0090-4295(18)31073.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: